Polyphenols, Alkaloids, and Terpenoids Against Neurodegeneration: Evaluating the Neuroprotective Effects of Phytocompounds Through a Comprehensive Review of the Current Evidence

Metabolites, Journal Year: 2025, Volume and Issue: 15(2), P. 124 - 124

Published: Feb. 13, 2025

Neurodegenerative diseases comprise a group of chronic, usually age-related, disorders characterized by progressive neuronal loss, deformation structure, or loss function, leading to substantially reduced quality life. They remain significant focus scientific and clinical interest due their increasing medical social importance. Most neurodegenerative present intracellular protein aggregation extracellular deposition (plaques), such as α-synuclein in Parkinson's disease amyloid beta (Aβ)/tau aggregates Alzheimer's. Conventional treatments for conditions incur high costs are related the development several adverse effects. In addition, many patients irresponsive them. For these reasons, there is growing tendency find new therapeutic approaches help patients. This review intends investigate some phytocompounds' effects on diseases. These generally increased oxidative stress inflammation, so phytocompounds can prevent treat To achieve our aim provide critical assessment current literature about phytochemicals targeting neurodegeneration, we reviewed reputable databases, including PubMed, EMBASE, COCHRANE, seeking trials that utilized against conditions. A few investigated humans, after screening, 13 were ultimately included following PRISMA guidelines. compounds include polyphenols (flavonoids luteolin quercetin, phenolic acids rosmarinic acid, ferulic caffeic other like resveratrol), alkaloids (such berberine, huperzine A, caffeine), terpenoids ginkgolides limonene). The gathered evidence underscores caffeine, ginkgolides, primarily anti-inflammatory, antioxidant, neuroprotective, counteracting neuroinflammation, oxidation, synaptic dysfunctions, which crucial aspects intervention various conditions, Alzheimer's dementias, depression, neuropsychiatric disorders. summary, they show use improvements cognition, memory, disinhibition, irritability/lability, aberrant behavior, hallucinations, mood

Language: Английский

---

Harnessing artificial intelligence in Alzheimer's disease management: navigating ethical challenges in AI

AI and Ethics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Language: Английский

---

Simultaneous quantification of four urinary biomarkers related to oxidative stress using UHPLC-QqQ-MS/MS

Journal of Chromatography B, Journal Year: 2025, Volume and Issue: 1256, P. 124552 - 124552

Published: March 3, 2025

Language: Английский

---

Drug Delivery Targeting Neuroinflammation to Treat Brain Diseases

Bioconjugate Chemistry, Journal Year: 2024, Volume and Issue: 35(11), P. 1687 - 1698

Published: Oct. 8, 2024

Inflammation within the brain is a hallmark of wide range diseases. The complex role inflammatory processes in these conditions suggests that neuroinflammation could be valuable therapeutic target. While several promising anti-inflammatory agents have been identified, their clinical application diseases often hampered by inability to cross blood-brain barrier (BBB) and reach therapeutically effective concentrations at pathological sites. This limitation highlights urgent need for BBB-penetrating drug delivery systems designed target inflammation. review critically examines recent advances over past five years strategies aimed mitigating inflammation Alzheimer's disease ischemic stroke─two leading causes death disability worldwide. Additionally, we address key challenges this field, offering insights into future directions targeting treatment

Language: Английский

---